Product Images Erlotinib

This is a graph showing the Kaplan-Meier curves for overall survival of patients by treatment group in Study 3. The x-axis represents Overall Survival, measured in months. The y-axis represents the Survival Probability. The treatment groups are not specified. The number of patients in each group is also not determined. However, the number of patients at risk is listed for the Picebo and Edoib groups.*

The text describes a Kaplan-Meier survival analysis for patients in Study 4, comparing the treatment group with placebo. The graph shows the survival probability over time, with the X-axis representing overall survival in months and the Y-axis showing the probability of survival. The two groups are represented by different colored lines on the graph. The graph also includes a table indicating the number of patients at risk for each treatment group at each time point.*

The image shows Kaplan-Meier curves for overall survival of the 100 mg cohort in Study 5. The survival probability is plotted on the Y-axis with the time to overall survival in months on the X-axis. The graph shows the number of patients at risk in both the placebo and Erlotinib groups at different time intervals.*

This is a description of a medication with the brand name Erlotinib. It comes in the form of film-coated tablets, each containing 25 mg of erlotinib free base. The usual dosage and complete prescribing information can be found in the enclosed package insert. It is manufactured by Shipa Medicare Limited and distributed by Armas Pharmaceuticals, Inc. The medication should be stored at 25°C (77°F) with excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). The National Drug Code (NDC) for this medication is 72485-217-30. The code for this medication is TSIDRUGS/1/2013. It is distributed in a bottle containing 30 tablets.*